Pharmacokinetic model-predicted anticancer drug concentrations in human tumors

Clinical Cancer Research

Volumn 10, Issue 23, 2004, Pages 8048-8058

  Gallo, James M ^a,c   Vicini, Paolo ^b   Orlansky, Amy ^a   Li, Shaolan ^a   Zhou, Feng ^a   Ma, Jianguo ^a   Pulfer, Sharon ^a   Bookman, Michel A ^a   Guo, Ping ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; TEMOZOLOMIDE; TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DISPOSITION; DRUG INFUSION; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN CELL; HYBRID; MALE; MODEL; MONTE CARLO METHOD; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; TIME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARBOPLATIN; COMPUTER SIMULATION; CYCLOHEXANES; DACARBAZINE; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RATS; RATS, INBRED F344; RATS, NUDE; SESQUITERPENES; TOPOTECAN; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 9744235168     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0822     Document Type: Article

References (31)

1. Modit NB. Pharmacokinetics and metabolism in drug discovery and preclinical development. In: Schoenwald RD, editor. Pharmacokinetics in drug discovery and development. Boca Raton: CRC Press, 2002. p. 57-71.
2. White RE, Manitpisitkul P. Pharmacokinetic theory of cassette dosing in drug discovery screening. Drug Metab Dispos 2001;29:957-66.
3. Graham MA, Kaye SB. New approaches in preclinical and clinical pharmacokinetics. In: Workman P, Graham MA, editors. Pharmacokinetics and cancer chemotherapy, vol. 17. Plainview, NY: Cold Spring Harbor Press, 1993. p. 27-49.
4. Gallo JM, Etse JT, Doshi KJ, Boudninot FD, Chu CK. Hybrid pharmacokinetic model to describe anti-HIV nucleoside brain disposition following parent and prodrug administration in mice. Pharm Res 1991;8:247-53.
5. Wada DR, Ward DS. The hybrid model: a new pharmacokinetic model for computer-controlled infusion pumps. IEEE Trans Biomed Eng 1994;41:134-42.
6. Foster DM, Aamodt RL, Henkin RI, Berman M. Zinc metabolism in humans: a kinetic model. Am J Physiol 1979;237:R340-49.
7. Bertoldo A, Vicini P, Sambuceti G, Lammertsma AA, Parodi O, Cobelli C. Evaluation of compartmental and spectral analysis models of [18F]FDG kinetics for heart and brain studies with PET. IEEE Trans Biomed Eng 1998;45:1429-48.
8. Gallo JM. Pharmacokinetics: Model Structure and Transport Systems. In: Amidon GL, Lee PI, and Topp EM, editors. Transport processes in pharmaceutical systems, vol. 102. New York, NY: Marcel Dekker; 2000. p. 55-86.
9. Rowland M, Balant L, Peck C. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington DC, May 29-30, 2002). AAPS PharmSci. 2004;6:E6.
10. Theil FP, Guentert TW, Haddad S, Poulin P. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett 2003;138:29-49.
11. Rose GS, Tocco LM, Granger GA, et al. Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am J Obstet Gynecol 1996;175:593-9.
12. Ma J, Zhou-Li F, Klein-Szanto A, Gallo JM. Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor. Clin Exp Metastasis 1998;16: 559-68.
13. Athale UH, Stewart C, Kuttesch JF, et al. Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol 2002;20:88-95.
14. Simpson A, Twelves C, Boddy A, et al. Schedule dependency of carboplatin and topotecan: phase I and pharmacokinetic studies. Proc Am Soc Clin Oncol 1998;17:785.
15. Guo P, Li S, Gallo JM. Determination of carboplatin in plasma and tissues by HPLC-MS. J Chromatogr B Analyt Technol Biomed Life Sci 2003;783:43-52.
16. Rosing H, Doyle E, Davies BE, Beijnen JH. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. J Chromatogr 1995;668:107-15.
17. Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res 2001;61:5491-8.
18. Ma J, Li S, Reed K, Guo P, Gallo JM. Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide (TMZ) in subcutaneous and intracerebral human glioma xenograft models. J Pharmacol Exp Ther 2003;305:833-9.
19. Barrett PH, Bell BM, Cobelli C, et al. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism 1998;47:484-92.
20. van Warmerdam LJ, Verweij J, Schellens JH, et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 1995;35:237-45.
21. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002;8:641-61.
22. Elferink F, van der Vijgh WJ, Klein I, Vermorken JB, Gall HE, Pinedo HM. Pharmacokinetics of carboplatin after i.v. administration. Cancer Treat Rep 1987;71:1231-7.
23. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
24. Ando M, Minami H, Ando Y, et al. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. Clin Cancer Res 2000;6:4733-8.
25. Jen JF, Cutler DL, Pai SM, et al. Population pharmacokinetics of temozolomide in cancer patients. Pharm Res 2000;17:1284-9.
26. Bischoff KB, Brown RG. Drug distribution in mammals. Chem Eng Prog Symp 1966;62:33-45.
27. Fross RD, Warnke PC, Groothuis D. Blood flow and blood-to-tissue transport in 9L gliosarcomas: the role of the brain tumor model in drug delivery research. J Neurooncol 1991;11:185-97.
28. Weinstein JN, Myers TG, O'Connor PM, et al. An information-intensive approach to the molecular pharmacology of cancer. Science (Wash D C) 1997;275:343-9.
29. Houghton PJ, Adamson PC, Blaney S, et al. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res 2002;8:3646-57.
30. Lin JH. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 1998;26: 1202-12.
31. Sukbuntherng J, Cropp G, Hannah A, Wagner GS, Shawver LK, Antonian L. Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416. J Pharm Pharmacol 2001;53:1629-36.